• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Cognition Therapeutics (CGTX)

Common Shares
Sell: $1.65|Buy: $1.72|Change: 0.07 (4.32%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Address




Website

https://www.cogrx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Cognition Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Cognition Therapeutics Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Cognition Therapeutics Inc Annual General Meeting for 20262026-06-18T09:00:00
Cognition Therapeutics Inc First Quarter Earnings Results for 20262026-05-07T00:00:00
Cognition Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-20T08:00:00
Cognition Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-20T00:00:00
Cognition Therapeutics Inc Annual Report for 20252026-03-20T00:00:00
37th Annual Piper Sandler Healthcare Conference2025-12-03T16:30:00

Previous key dates

NameKey Date
37th Annual Piper Sandler Healthcare Conference2025-12-03T16:30:00
Cognition Therapeutics Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
Cognition Therapeutics Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
Cognition Therapeutics Inc Annual General Meeting for 20252025-06-18T09:00:00
Cognition Therapeutics Inc First Quarter Earnings Results for 20252025-05-07T00:00:00
Cognition Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-03-20T08:00:00
Cognition Therapeutics Inc Fourth Quarter Earnings Result for 20242025-03-20T00:00:00
Cognition Therapeutics Inc Annual Report for 20242025-03-20T00:00:00
Life Sciences Virtual Investor Conference2025-03-13T09:30:00
Analysis of Topline Phase 2 DLB Results2024-12-18T08:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.